AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2003 DEC 10 - (NewsRx.com & NewsRx.net) -- With an estimated 170 million people around the world already infected with hepatitis C, St. Louis University is testing, for the first time in humans, an investigational vaccine that researchers hope will prevent infection with the virus. The successful development of such a vaccine would represent a major step in combating this growing health problem.
St. Louis University is the only site in the country conducting this pilot study.
"There is currently no licensed vaccine to protect against the hepatitis C virus," said Sharon Frey, MD, principal investigator for the study and associate professor of internal medicine at St. Louis University School of Medicine. "Our research is important because infection with hepatitis C virus is a major health problem throughout the world. It is believed that 2.7 million Americans have chronic infection with this virus, and ...
Source: HighBeam Research, New investigational vaccine tested for first time in humans.